Table 1.

Resistant cell lines

Parental cell line	RRID	Origin	Therapy drug	Parental IC50	Therapy target	Exposure period	Resistant cell line	Resistant IC50	EMT	Ref
HepG2 (n = 2)	CVCL_0027	Liver	Sorafenib	0.28 μM	VEGFR, PDGFR, Raf kinases	6–12 months	HepG2S1	0.44 μM	Full	[16]
							HepG2S3	0.69 μM	Full
HCC4006P1	CVCL_1269	Lung	Erlotinib	0.03 μM	EGFR	3–6 months	HCC4006ER	0.97 μM	Full	[17]
Panc 03.27 (‘PancVB’) (n = 2)	CVCL_1635	Pancreas	5-Fluorouracil	14.63 μM	Thymidylate synthase	6 months	PancB1Q	55.72 μM	Full	[18]
							PancB1V	30.75 μM	Full
HCC4006P2	CVCL_1269	Lung	Gefitinib	0.10 μM	EGFR	3 months	HCC4006GR	0.59 μM	Full	[19]
HCC827P	CVCL_2063	Lung	Gefitinib	0.027 μM	EGFR	3 months	HCC827GR	0.046 μM	Full
UWB 1.289 (n = 2)	CVCL_B079	Ovary	Olaparib	58.02 μM	PARP	5 months	U10	512.33 μM	Partial	[20]
							U100	699.41 μM	Partial
IGROV-1	CVCL_1304	Ovary	Cisplatin	64.04 μM	DNA replication	9 months	IGROV-1/CDDP	388.02 μM	Partial	[21]

The columns indicate which established cell line was used as the parental cell line, their Research Resource Identifiers (RRID), their tissue of origin, the drug they were made resistant to, the concentration of the drugs at which their growth was inhibited by 50% (IC₅₀), the target of the drug, the period over which they were rendered resistant, the name of their resistant counterparts, the concentration of drugs at which the growth of the resistant cells was inhibited by 50% (IC₅₀), their EMT status and the reference of the paper describing their retrieval